PCM
PLRX icon

Pentwater Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Pentwater Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,500
Closed -$189K – 267
2021
Q2 		$189K Buy
+6,500
New +$202K ﹤0.01% 286

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Pentwater Capital Management's PLRX Position: Q3 2023 in Review

Pentwater Capital Management sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 25,000 shares — an estimated $453K sold.

Pentwater Capital Management first reported a position in PLRX in Q2 2020 and held it in 9 quarters. The position peaked at $1.31M in Q2 2020. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • Pentwater Capital Management reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Pentwater Capital Management sold 25,000 Pliant Therapeutics shares in Q3 2023, an estimated $453K.
  • Pentwater Capital Management first reported a position in Pliant Therapeutics in Q2 2020 and held it in 9 quarters.
  • Pentwater Capital Management's Pliant Therapeutics position peaked at $1.31M in Q2 2020.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Pentwater Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.